Lamivudine use in pregnant HBsAg-females effectively reduces maternal viremia-Science-Chemical Encyclopedia-lookchem

Lamivudine (cas 134678-17-4) use in pregnant HBsAg-females effectively reduces maternal viremia
Add time:07/30/2019 Source:sciencedirect.com

Background and study aimsMother-infant hepatitis B virus (HBV) transmission is the current leading cause of chronic infection. We aimed to assess the efficacy of Lamivudine (cas 134678-17-4) use in hepatitis B surface antigen (HBsAg)-positive pregnant women to decrease viral load and thus aid in the prevention of transmission.

We also recommend Trading Suppliers and Manufacturers of Lamivudine (cas 134678-17-4). Pls Click Website Link as below: cas 134678-17-4 suppliers

Prev:Reactions of 6-(tri- and 6-(difluoromethyl))comanic acids and their ethyl esters with aniline and its 2-substituted derivatives
Next: Preparation of the enantiomerically enriched precursor of Lamivudine (cas 134678-17-4) (3TC™) via asymmetric catalysis mediated by Klebsiella oxytoca)

Click to view details

Health and Chemicalmore >